Petros Pharmaceuticals (PTPI) awards 500,000 RSUs to President & CCO

Rhea-AI Filing Summary

Petros Pharmaceuticals, Inc. reported an equity grant to one of its senior executives. Officer Fady Boctor, who serves as President & Chief Commercial Officer, received 500,000 restricted stock units (RSUs) of Petros common stock on 01/02/2026 at a stated price of $0 per unit.

According to the terms, 50% of these RSUs vested on the grant date, and the remaining 50% will vest on the six‑month anniversary of the grant date if he is still providing services to the company. Each RSU gives the right to receive one share of common stock. After this grant, Boctor beneficially owned 519,986 shares of Petros common stock, with amounts adjusted for the company’s 1‑for‑25 reverse stock split that became effective at 4:05 p.m. New York time on April 30, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boctor Fady

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS, 3RD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Petros Pharmaceuticals, Inc. [ PTPI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		500,000(1)	A	$0(1)	519,986(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

2. Amounts adjusted for the Issuer's 1-for-25 reverse stock split of the Issuer's Common Stock, effective as of 4:05 p.m. (New York time) on April 30, 2025.

Remarks:

President & Chief Commercial Officer

	/s/ Fady Boctor	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Petros Pharmaceuticals (PTPI) report in this Form 4?

The company reported that President & Chief Commercial Officer Fady Boctor received 500,000 restricted stock units (RSUs) of Petros common stock on 01/02/2026 at a stated price of $0 per unit.

How do the 500,000 RSUs granted to Fady Boctor at Petros Pharmaceuticals (PTPI) vest?

50% of the RSUs vested on the grant date, and the remaining 50% will vest on the six‑month anniversary of the grant date, as long as Fady Boctor is still providing services to Petros Pharmaceuticals on that vesting date.

What does each RSU granted by Petros Pharmaceuticals (PTPI) to Fady Boctor represent?

Each RSU represents the right to receive one share of Petros Pharmaceuticals common stock, par value $0.0001 per share.

How many Petros Pharmaceuticals (PTPI) shares does Fady Boctor beneficially own after this RSU grant?

Following the reported transaction, Fady Boctor beneficially owned 519,986 shares of Petros Pharmaceuticals common stock, adjusted for the company’s 1‑for‑25 reverse stock split.

What reverse stock split did Petros Pharmaceuticals (PTPI) disclose in connection with this Form 4?

The share amounts were adjusted for Petros Pharmaceuticals’ 1‑for‑25 reverse stock split of its common stock, which was effective as of 4:05 p.m. New York time on April 30, 2025.

What is Fady Boctor’s role at Petros Pharmaceuticals (PTPI) as noted in the Form 4?

Fady Boctor is identified as an officer of Petros Pharmaceuticals, serving as President & Chief Commercial Officer.